End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.67 MYR | +2.29% | -0.74% | -2.90% |
04-17 | Rhone Ma to Pay Final Dividend | MT |
04-16 | Rhone Ma Holdings Berhad Announces Final Single Tier Dividend in Respect of the Financial Year Ended 31 December 2023, Payable on July 15, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.90% | 31.27M | - | ||
+32.36% | 695B | C+ | ||
+26.51% | 568B | B | ||
-4.40% | 361B | C+ | ||
+19.46% | 330B | B- | ||
+3.50% | 283B | C+ | ||
+16.34% | 239B | B+ | ||
+6.68% | 204B | B- | ||
-9.08% | 198B | A+ | ||
+8.62% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- RHONEMA Stock
- Ratings Rhone Ma Holdings